Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Keeps Buy on HENGRUI PHARMA, Adds TP to HKD97.4
Recommend 6 Positive 4 Negative 4 |
||||
|
||||
|
According to a report from UBS, HENGRUI PHARMA (01276.HK) recorded 1Q revenue of RMB8.14 billion, up 13% YoY, shy of market expectations of RMB8.53 billion and the broker's forecast of RMB8.81 billion. HENGRUI PHARMA's net profit increased by 21.8% to RMB2.28 billion, broadly in line with market expectations of RMB2.18 billion and UBS' forecast of RMB2.33 billion. Gross margin for 1Q26 rose by 1.4 ppts YoY to 86.6%, while net margin increased by 2 ppts to 28%. UBS lifted HENGRUI PHARMA's target price to HKD97.4 from HKD91, with a Buy rating remaining in place. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
